-
Company Profile
Galmed Pharmaceuticals Ltd – Company Profile
Galmed Pharmaceuticals Ltd (Galmed Pharmaceuticals) is a clinical-stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. The company focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with nonalcoholic steatohepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial,...
Add to Basket -
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
NAFLD Clinical Trials Market Report Overview The NAFLD clinical trial market research report provides an overview of the NAFLD clinical trials scenario. The report provides top-line data relating to the clinical trials on NAFLD. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Net Present Value Model: Aramchol
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Aramchol Drug Details Aramchol is under...
-
Product Insights
Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, a tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea, and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aramchol Meglumine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Aramchol Meglumine Drug Details Aramchol meglumine is under development for the treatment of nonalcoholic...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Aramchol
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Aramchol Drug Details Aramchol is under development for the treatment of non-alcoholic steatohepatitis (NASH),...
-
Product Insights
Transthyretin (ATTR or Prealbumin or TBPA or TTR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Transthyretin is a transport protein that transports thyroid hormones and retinol (vitamin A). The Transthyretin pipeline drugs market research report outlays comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development with respective active and dormant or discontinued...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort. The NAFLD drugs in development market research report provides comprehensive information on the therapeutics under development for the NAFLD, complete...